These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3677504)

  • 1. Pharmacokinetic disposition of isoxicam in hepatic cirrhosis.
    Esquivel M; Ogilvie RI; East DS; Shaw DH; Heathcote J
    Clin Invest Med; 1987 Sep; 10(5):363-7. PubMed ID: 3677504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of isoxicam with acetylsalicylic acid.
    Esquivel M; Cussenot F; Ogilvie RI; East DS; Shaw DH
    Br J Clin Pharmacol; 1984 Oct; 18(4):567-71. PubMed ID: 6487496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lowering of plasma isoxicam concentrations with acetylsalicylic acid.
    Grace EM; Mewa AA; Sweeney GD; Rosenfeld JM; Darke AC; Buchanan WW
    J Rheumatol; 1986 Dec; 13(6):1119-21. PubMed ID: 3560102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic disposition of the non-steroidal anti-inflammatory agent isoxicam in man.
    Woolf TF; Black A; Sedman A; Chang T
    Eur J Drug Metab Pharmacokinet; 1992; 17(1):21-7. PubMed ID: 1499594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiency.
    Brooks PM; McCredie M; Prowse M; Podgorski M; Forrest M; Munro I; Boutagy J; Pei-Ling L
    Pharmatherapeutica; 1986; 4(10):665-72. PubMed ID: 3602018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of isoxicam following intravenous, intramuscular, oral and rectal administration in healthy volunteers.
    Kölle EU; Vollmer KO
    Br J Clin Pharmacol; 1986; 22 Suppl 2(Suppl 2):135S-141S. PubMed ID: 3620273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of administration of phenytoin on the pharmacokinetics of isoxicam.
    Caillé G; Du Souich P; Larivière L; Vézina M; Lacasse Y
    Biopharm Drug Dispos; 1987; 8(1):57-61. PubMed ID: 3580513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theophylline disposition in patients with hepatic cirrhosis.
    Piafsky KM; Sitar DS; Rangno RE; Ogilvie RI
    N Engl J Med; 1977 Jun; 296(26):1495-7. PubMed ID: 865528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of isoxicam in hepatic disease.
    Ferry N; Cuisinaud G; Ouzan D; Trepo C; Sassard J
    Br J Clin Pharmacol; 1986; 22 Suppl 2(Suppl 2):143S-147S. PubMed ID: 2887185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.
    Perini JA; Vianna-Jorge R; Brogliato AR; Suarez-Kurtz G
    Clin Pharmacol Ther; 2005 Oct; 78(4):362-9. PubMed ID: 16198655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma and synovial fluid concentrations of isoxicam in meniscectomized patients.
    Ballerini R; Casini A; Chinol M; Mannucci C; Melani F; Ungar F
    Drugs Exp Clin Res; 1985; 11(8):517-21. PubMed ID: 3841790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of isoxicam pharmacokinetics in young and elderly subjects.
    George CF; Renwick AG; Darragh AS; Hosie J; Blake D; van Marle W; Frank GJ
    Br J Clin Pharmacol; 1986; 22 Suppl 2(Suppl 2):129S-134S. PubMed ID: 3620272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-steroidal anti-inflammatory drugs: restrictive or non-restrictive hepatic clearance?
    Verbeeck RK; Wallace SM
    Arzneimittelforschung; 1994 May; 44(5):683-5. PubMed ID: 8024649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Skin penetration of sulfamethoxazole and trimethoprim after oral administration].
    Królicki A
    Ann Acad Med Stetin; 2002; 48():59-73. PubMed ID: 14601469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolism of riboflavin in female patients with liver cirrhosis.
    Zempleni J; Galloway JR; McCormick DB
    Int J Vitam Nutr Res; 1996; 66(3):237-43. PubMed ID: 8899458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam.
    Crevoisier C; Zaugg PY; Heizmann P; Meyer J
    Int J Clin Pharmacol Res; 1989; 9(5):327-34. PubMed ID: 2625372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flunoxaprofen pharmacokinetics in elderly subjects.
    Segre G; Bianchi E; Mascaretti L; Quaglia G; Forgione A
    Int J Clin Pharmacol Res; 1987; 7(4):243-50. PubMed ID: 3596866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
    Kharasch ED; Hoffer C; Walker A; Sheffels P
    Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the CYP2C9*3 allele on lornoxicam metabolism.
    Liu YL; Zhang W; Tan ZR; Ouyang DS; Luo CH; Liu ZQ; Qiu Y; Chen Y; He YJ; Zhou G; Zhou HH
    Clin Chim Acta; 2006 Feb; 364(1-2):287-91. PubMed ID: 16182270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.